Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): pubmed.ncbi.nlm.nih.gov/34469919/.
Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: pubmed.ncbi.nlm.nih.gov/34516272/.
Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: pubmed.ncbi.nlm.nih.gov/34512961/
Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: pubmed.ncbi.nlm.nih.gov/34350668/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/.
COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: pubmed.ncbi.nlm.nih.gov/34509271/.
Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34462996/
COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: pubmed.ncbi.nlm.nih.gov/34435142/
Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34236711/
Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: pubmed.ncbi.nlm.nih.gov/33857630/.
The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34455073/
Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: pubmed.ncbi.nlm.nih.gov/34116145/
Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: pubmed.ncbi.nlm.nih.gov/34286453/.
Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: pubmed.ncbi.nlm.nih.gov/34478433/
Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: pubmed.ncbi.nlm.nih.gov/34244448/
Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34226070/
Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: pubmed.ncbi.nlm.nih.gov/34393988/.
Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: pubmed.ncbi.nlm.nih.gov/34407607/.
Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: pubmed.ncbi.nlm.nih.gov/34313952/
Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): pubmed.ncbi.nlm.nih.gov/34092166/
Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: pubmed.ncbi.nlm.nih.gov/34293217/
A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: pubmed.ncbi.nlm.nih.gov/34274191/
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: pubmed.ncbi.nlm.nih.gov/34186376/
Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: pubmed.ncbi.nlm.nih.gov/33952445/
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: pubmed.ncbi.nlm.nih.gov/34129181/
U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination...
#6 U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: pubmed.ncbi.nlm.nih.gov/33929487/.
Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34341358/
Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: pubmed.ncbi.nlm.nih.gov/34175640/
Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/.
Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/
Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: pubmed.ncbi.nlm.nih.gov/34373991/
Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34490632/
An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33909350/
Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: pubmed.ncbi.nlm.nih.gov/33981305/.
A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. pubmed.ncbi.nlm.nih.gov/34272622/
Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. pubmed.ncbi.nlm.nih.gov/33877737/
Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34254476/
First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: pubmed.ncbi.nlm.nih.gov/34108714/
ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: pubmed.ncbi.nlm.nih.gov/34483267/.
Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261635/
Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: pubmed.ncbi.nlm.nih.gov/34202817/
A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34276917/
Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34237213/.
Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34268278/.
Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/33990339/.
Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: pubmed.ncbi.nlm.nih.gov/34479760/.
Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: pubmed.ncbi.nlm.nih.gov/34314875/.
Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: pubmed.ncbi.nlm.nih.gov/34382387/
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/.
Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/
Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: t.co/j0IEM8cMXI
A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: pubmed.ncbi.nlm.nih.gov/34601006/
This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: www.nejm.org/doi/full/10.1056/NEJMoa2110475
Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: pubmed.ncbi.nlm.nih.gov/34626338/
A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: europepmc.org/article/PPR/PPR304469 435.
Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/
Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34461442/
Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34373413/
Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34598301/
Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca...
Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: pubmed.ncbi.nlm.nih.gov/34696248/
Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: pubmed.ncbi.nlm.nih.gov/34545400/
Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34035134/
In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34688190/
Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: pubmed.ncbi.nlm.nih.gov/34782400/
Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: pubmed.ncbi.nlm.nih.gov/34710832/
Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: pubmed.ncbi.nlm.nih.gov/34644642/
Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34726934/
Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: pubmed.ncbi.nlm.nih.gov/34835237/
Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/
Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34724036/.
COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: pubmed.ncbi.nlm.nih.gov/34624910/
Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34580132/.
A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: pubmed.ncbi.nlm.nih.gov/34535492/
Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: pubmed.ncbi.nlm.nih.gov/34272095/
Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: pubmed.ncbi.nlm.nih.gov/34756770/
Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: pubmed.ncbi.nlm.nih.gov/34706921/
COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: pubmed.ncbi.nlm.nih.gov/34698582/.
Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: pubmed.ncbi.nlm.nih.gov/34327553/.
Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33877737/
Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34646685/
Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34242687/.
Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): pubmed.ncbi.nlm.nih.gov/34006408/
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/
Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: pubmed.ncbi.nlm.nih.gov/34664303/.
Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34649281/.
Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: pubmed.ncbi.nlm.nih.gov/34420249/
Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: pubmed.ncbi.nlm.nih.gov/34610990/.
Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: pubmed.ncbi.nlm.nih.gov/34819146/.
Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: pubmed.ncbi.nlm.nih.gov/34755433/
Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: pubmed.ncbi.nlm.nih.gov/34667486/
Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: pubmed.ncbi.nlm.nih.gov/34726187/.
Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: pubmed.ncbi.nlm.nih.gov/34595694/
Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: pubmed.ncbi.nlm.nih.gov/34661934/
Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34788138
A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: pubmed.ncbi.nlm.nih.gov/34769454/
Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: pubmed.ncbi.nlm.nih.gov/34833382/
Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): pubmed.ncbi.nlm.nih.gov/34670287/
Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: pubmed.ncbi.nlm.nih.gov/34023956/.
Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/
Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34842783/
Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34630307/
Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: pubmed.ncbi.nlm.nih.gov/34579248/
A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: pubmed.ncbi.nlm.nih.gov/34843991/
Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34407607/
Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: pubmed.ncbi.nlm.nih.gov/34639132/
Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: pubmed.ncbi.nlm.nih.gov/34804412/
Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/
Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/
Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: pubmed.ncbi.nlm.nih.gov/34712717/.
Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: pubmed.ncbi.nlm.nih.gov/34219532/
Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/
Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/
CAd26.COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: pubmed.ncbi.nlm.nih.gov/34632750/
Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: pubmed.ncbi.nlm.nih.gov/34887867/.
Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34880826/
Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: pubmed.ncbi.nlm.nih.gov/34868465/
Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34097311/
Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: pubmed.ncbi.nlm.nih.gov/34820232/.
Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: onlinelibrary.wiley.com/doi/10.1002/ajh.26258
Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: pubmed.ncbi.nlm.nih.gov/34614491/
Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: pubmed.ncbi.nlm.nih.gov/34790684/
Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): pubmed.ncbi.nlm.nih.gov/34612003/
Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: pubmed.ncbi.nlm.nih.gov/34096082/
Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34496880/
Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: pubmed.ncbi.nlm.nih.gov/34664804/
Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: pubmed.ncbi.nlm.nih.gov/34166671/
Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34746968/
Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: pubmed.ncbi.nlm.nih.gov/34333695/.
Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34180390/
Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: pubmed.ncbi.nlm.nih.gov/34866106/
Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: pubmed.ncbi.nlm.nih.gov/34487236/
Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: pubmed.ncbi.nlm.nih.gov/34848416/
Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: pubmed.ncbi.nlm.nih.gov/34636504/
Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34367386/
Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: pubmed.ncbi.nlm.nih.gov/34778411/
Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: pubmed.ncbi.nlm.nih.gov/34796417/.
#11 A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): pubmed.ncbi.nlm.nih.gov/34871447/
Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: pubmed.ncbi.nlm.nih.gov/34579259/
Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: pubmed.ncbi.nlm.nih.gov/34810163/
Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: pubmed.ncbi.nlm.nih.gov/34722067/
Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: pubmed.ncbi.nlm.nih.gov/33968610/
SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: pubmed.ncbi.nlm.nih.gov/34525410/
Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: pubmed.ncbi.nlm.nih.gov/34808658/
Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: pubmed.ncbi.nlm.nih.gov/34621891/
Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: pubmed.ncbi.nlm.nih.gov/34189662/
Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: pubmed.ncbi.nlm.nih.gov/34660149/
Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34131771/
A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: pubmed.ncbi.nlm.nih.gov/34635376/
Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34848426/.
Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/33946748/
Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34859017/
Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34729467/.
Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: pubmed.ncbi.nlm.nih.gov/33771584/
Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: pubmed.ncbi.nlm.nih.gov/34411532/
Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: pubmed.ncbi.nlm.nih.gov/33641264/
Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: pubmed.ncbi.nlm.nih.gov/33641268/
Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: pubmed.ncbi.nlm.nih.gov/33834172/
Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: pubmed.ncbi.nlm.nih.gov/34579211/
Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: pubmed.ncbi.nlm.nih.gov/34343674/
*
Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34325334/
Tolosa-Hunt syndrome occurring after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34513398/
Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): pubmed.ncbi.nlm.nih.gov/34469919/.
Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: pubmed.ncbi.nlm.nih.gov/34516272/.
Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: pubmed.ncbi.nlm.nih.gov/34512961/
Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34077949/
Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34171435/
Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34447349/
Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34514078/
Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34406660/.
IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34509658/
A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34196469/.
Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: pubmed.ncbi.nlm.nih.gov/34350668/
Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34436620/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/.
COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: pubmed.ncbi.nlm.nih.gov/34509271/.
Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34462996/
Immune thrombocytopenia after vaccination during the COVID-19 pandemic: pubmed.ncbi.nlm.nih.gov/34435486/
COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: pubmed.ncbi.nlm.nih.gov/34435142/
Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34429981/
Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: pubmed.ncbi.nlm.nih.gov/34427024/
Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34510014/.
Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34236711/
Vaccine-induced thrombocytopenia with severe headache: pubmed.ncbi.nlm.nih.gov/34525282/
Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34515024/
Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34435250/.
Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34363637/
Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: www.sciencedirect.com/science/article/pii/S2214250921002018
Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: casereports.bmj.com/content/14/5/e242220.abstract.
Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34155844/
Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/.
Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext.
Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/.
Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: casereports.bmj.com/content/14/7/e242678.
Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-
Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794
COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines
Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: pubmed.ncbi.nlm.nih.gov/34288044/.
Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: pubmed.ncbi.nlm.nih.gov/34327553/.
Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33878469/.
Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: pubmed.ncbi.nlm.nih.gov/33857630/.
Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34090750/.
Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34312301/.
Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34333995/
The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34455073/
Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34111775/.
Cerebral venous thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34045111/
Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33983464/
Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: pubmed.ncbi.nlm.nih.gov/34116145/
Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: pubmed.ncbi.nlm.nih.gov/34286453/.
Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: pubmed.ncbi.nlm.nih.gov/34478433/
Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: pubmed.ncbi.nlm.nih.gov/34244448/
Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34226070/
Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: pubmed.ncbi.nlm.nih.gov/33845870/.
Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34101024/.
Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: pubmed.ncbi.nlm.nih.gov/34393988/.
Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: pubmed.ncbi.nlm.nih.gov/34407607/.
Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: pubmed.ncbi.nlm.nih.gov/34313952/
Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): pubmed.ncbi.nlm.nih.gov/34092166/
Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: pubmed.ncbi.nlm.nih.gov/34293217/
A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: pubmed.ncbi.nlm.nih.gov/34274191/
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: pubmed.ncbi.nlm.nih.gov/34186376/
Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: pubmed.ncbi.nlm.nih.gov/33952445/
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: pubmed.ncbi.nlm.nih.gov/34129181/
U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination...
*
Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34341358/
Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: pubmed.ncbi.nlm.nih.gov/34175640/
Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/.
Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/
Autoimmunity roots of thrombotic events after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34508917/
Cerebral venous sinus thrombosis after vaccination: the UK experience: pubmed.ncbi.nlm.nih.gov/34370974/
Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: pubmed.ncbi.nlm.nih.gov/34373991/
Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34490632/
An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33909350/
Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: pubmed.ncbi.nlm.nih.gov/33981305/.
A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. pubmed.ncbi.nlm.nih.gov/34272622/
Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. pubmed.ncbi.nlm.nih.gov/33877737/
Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34254476/
First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: pubmed.ncbi.nlm.nih.gov/34108714/
ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: pubmed.ncbi.nlm.nih.gov/34483267/.
Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261635/
Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: pubmed.ncbi.nlm.nih.gov/34202817/
Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: pubmed.ncbi.nlm.nih.gov/34273119/
Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: pubmed.ncbi.nlm.nih.gov/34463066/
A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34276917/
Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34237213/.
Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34268278/.
Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/33990339/.
Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: pubmed.ncbi.nlm.nih.gov/34479760/.
Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: pubmed.ncbi.nlm.nih.gov/34314875/.
Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34384129/
Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: pubmed.ncbi.nlm.nih.gov/34382387/
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/.
Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/
Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34261296/
Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: pubmed.ncbi.nlm.nih.gov/34250318/.
A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: pubmed.ncbi.nlm.nih.gov/34059191/
Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34189756/
Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34331506/
Vaccine-induced thrombocytopenia with severe headache: pubmed.ncbi.nlm.nih.gov/34525282/
Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: www.medrxiv.org/content/10.1101/2021.08.30.21262866v1
COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09.
Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: onlinelibrary.wiley.com/doi/10.1111/trf.16672
Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: t.co/j0IEM8cMXI
A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: pubmed.ncbi.nlm.nih.gov/34601006/
This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: www.nejm.org/doi/full/10.1056/NEJMoa2110475
Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: www.sciencedirect.com/science/article/pii/S1201971221007797
Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: www.medrxiv.org/content/10.1101/2021.08.30.21262866v1.
Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: www.sciencedirect.com/science/article/pii/S0168827821020936
Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: www.nature.com/articles/s41421-021-00329-3
Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/
Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution: www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome:www.science.org/doi/10.1126/sciadv.abl8213
Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: pubmed.ncbi.nlm.nih.gov/34626338/
A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: europepmc.org/article/PPR/PPR304469 435.
VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34731555/
Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/
Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34461442/
Spectrum of neurological complications after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34719776/.
Cerebral venous sinus thrombosis after vaccination: the UK experience: pubmed.ncbi.nlm.nih.gov/34370974/
Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34373413/
Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34598301/
Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca...
*
Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: pubmed.ncbi.nlm.nih.gov/34650896/
Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34625447/
Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: pubmed.ncbi.nlm.nih.gov/34696248/
Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34548920/
Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): pubmed.ncbi.nlm.nih.gov/34672380/.
Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: pubmed.ncbi.nlm.nih.gov/34556531/.
Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: pubmed.ncbi.nlm.nih.gov/34535076/.
Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: pubmed.ncbi.nlm.nih.gov/34379914/.
Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: pubmed.ncbi.nlm.nih.gov/34545400/
Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34035134/
In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34688190/
Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: pubmed.ncbi.nlm.nih.gov/34782400/
Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: pubmed.ncbi.nlm.nih.gov/34710832/
Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: pubmed.ncbi.nlm.nih.gov/34695859/
Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: pubmed.ncbi.nlm.nih.gov/34453762/.
Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: pubmed.ncbi.nlm.nih.gov/34660652/.
Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: pubmed.ncbi.nlm.nih.gov/34644642/
Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: pubmed.ncbi.nlm.nih.gov/34694650/
Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34726934/
Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: pubmed.ncbi.nlm.nih.gov/34835237/
Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/
Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34724036/.
Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34839563/
Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34783932/.
COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: pubmed.ncbi.nlm.nih.gov/34624910/
Inflammatory myositis after vaccination with ChAdOx1: pubmed.ncbi.nlm.nih.gov/34585145/
Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34580132/.
A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: pubmed.ncbi.nlm.nih.gov/34535492/
COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: pubmed.ncbi.nlm.nih.gov/34527501/
Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: pubmed.ncbi.nlm.nih.gov/34272095/
Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: pubmed.ncbi.nlm.nih.gov/34756770/
Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: jamanetwork.com/journals/jamaneurology/fullarticle/2784622
Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34781321/
Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: pubmed.ncbi.nlm.nih.gov/34062319/
Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: pubmed.ncbi.nlm.nih.gov/34706921/
COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: pubmed.ncbi.nlm.nih.gov/34698582/.
Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34751013/.
Acute transverse myelitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34684047/.
Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34541935/
Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34273119/
Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: pubmed.ncbi.nlm.nih.gov/34327553/.
Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33877737/
Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34646685/
Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34242687/.
Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34609603/
Case report: Pityriasis rosea-like rash after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34557507/
Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34641797/.
Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: pubmed.ncbi.nlm.nih.gov/34812326/.
Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): pubmed.ncbi.nlm.nih.gov/34006408/
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/
Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: pubmed.ncbi.nlm.nih.gov/34664303/.
Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34649281/.
Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: pubmed.ncbi.nlm.nih.gov/34420249/
Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: pubmed.ncbi.nlm.nih.gov/34610990/.
Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: pubmed.ncbi.nlm.nih.gov/34590397/
Sudden sensorineural hearing loss after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34670143/.
Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: pubmed.ncbi.nlm.nih.gov/34819146/.
Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: pubmed.ncbi.nlm.nih.gov/34581453/
Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: pubmed.ncbi.nlm.nih.gov/34741583/
Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: pubmed.ncbi.nlm.nih.gov/34631069/
Thrombosis after COVID-19 vaccination: possible link to ACE pathways: pubmed.ncbi.nlm.nih.gov/34479129/
Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34331506/
Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): pubmed.ncbi.nlm.nih.gov/34546608/
Abdominal pain and bilateral...
*
Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34849183/
Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34853744/.
A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): pubmed.ncbi.nlm.nih.gov/34751429/.
Ocular adverse events following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34559576/
Depression after ChAdOx1-S / nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34608345/.
Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34384129/.
Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: pubmed.ncbi.nlm.nih.gov/34755433/
Major artery thrombosis and vaccination against ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34839830/
Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: pubmed.ncbi.nlm.nih.gov/34667486/
Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: pubmed.ncbi.nlm.nih.gov/34726187/.
Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34781027/
Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: pubmed.ncbi.nlm.nih.gov/34595694/
Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: pubmed.ncbi.nlm.nih.gov/34661934/
Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34788138
Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34753210/.
Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34653943/.
Relapse of immune thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34591991/
Thrombosis in pre- and post-vaccination phase of COVID-19; pubmed.ncbi.nlm.nih.gov/34650382/
A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: pubmed.ncbi.nlm.nih.gov/34769454/
COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: pubmed.ncbi.nlm.nih.gov/34786893/
Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: pubmed.ncbi.nlm.nih.gov/34833382/
Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): pubmed.ncbi.nlm.nih.gov/34670287/
An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34790811/
Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: pubmed.ncbi.nlm.nih.gov/34023956/.
Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: pubmed.ncbi.nlm.nih.gov/34629931/
Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/
Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34842783/
Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34630307/
Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33983464/
Autoimmune roots of thrombotic events after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34508917/.
New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext.
Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca
Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: pubmed.ncbi.nlm.nih.gov/34796065/.
Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: pubmed.ncbi.nlm.nih.gov/34579248/
A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: pubmed.ncbi.nlm.nih.gov/34843991/
Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): pubmed.ncbi.nlm.nih.gov/34595867/
A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): pubmed.ncbi.nlm.nih.gov/34820240/
Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors: pubmed.ncbi.nlm.nih.gov/33851389/
Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: pubmed.ncbi.nlm.nih.gov/33980419/
Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34264151/
Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: pubmed.ncbi.nlm.nih.gov/34734086/
Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: pubmed.ncbi.nlm.nih.gov/34755555/
Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34407607/
Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: pubmed.ncbi.nlm.nih.gov/34264514/.
Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): pubmed.ncbi.nlm.nih.gov/34840204/
Neurological side effects of SARS-CoV-2 vaccines: pubmed.ncbi.nlm.nih.gov/34750810/
Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: pubmed.ncbi.nlm.nih.gov/34639132/
Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: pubmed.ncbi.nlm.nih.gov/34804412/
Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: pubmed.ncbi.nlm.nih.gov/34571653/.
Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: pubmed.ncbi.nlm.nih.gov/34835275/.
Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: pubmed.ncbi.nlm.nih.gov/34659839/.
Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34668274/.
Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34549821/
Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): pubmed.ncbi.nlm.nih.gov/34528522/
Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/.
Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408
Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: www.mdpi.com/2075-4426/11/11/1106
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/
Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/
Myocarditis Following mRNA COVID-19 Vaccine: journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx.
Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: pubmed.ncbi.nlm.nih.gov/34614328/.
Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext
Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34277198/
Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: pubmed.ncbi.nlm.nih.gov/34246586/
Hypersensitivity Myocarditis and...
*
Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7.
Acute myocardial infarction and myocarditis after COVID-19 vaccination: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/
Myocarditis after Covid-19 vaccination in a large healthcare organization: www.nejm.org/doi/10.1056/NEJMoa2110737
Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: jamanetwork.com/journals/jamacardiology/fullarticle/2783052
Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=
STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. pubmed.ncbi.nlm.nih.gov/34756746/
Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/
Myocarditis after COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34546329/.
Patients with acute myocarditis after COVID-19 mRNA vaccination:. jamanetwork.com/journals/jamacardiology/fullarticle/2781602.
Myocarditis after COVID-19 vaccination: a case series: www.sciencedirect.com/science/article/pii/S0264410X21011725?via=ihub.
Myocarditis associated with COVID-19 vaccination in adolescents: publications.aap.org/pediatrics/article/148/5/e2021053427/181357
Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. pubmed.ncbi.nlm.nih.gov/34704459/
Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230.
Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/
Myocarditis after COVID-19 vaccination: www.sciencedirect.com/science/article/pii/S2352906721001603
Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: pubmed.ncbi.nlm.nih.gov/34712717/.
Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administ.
Myocarditis associated with COVID-19 mRNA vaccination: pubs.rsna.org/doi/10.1148/radiol.2021211430
Acute myocarditis after COVID-19 vaccination: a case report: www.sciencedirect.com/science/article/pii/S0248866321007098
Acute myopericarditis after COVID-19 vaccination in adolescents:. pubmed.ncbi.nlm.nih.gov/34589238/.
Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: academic.oup.com/jpids/article/10/10/962/6329543.
Acute myocarditis associated with anti-COVID-19 vaccination: ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196.
Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. pubmed.ncbi.nlm.nih.gov/34428917/.
Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. pubmed.ncbi.nlm.nih.gov/34088762/.
Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:. academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/6.
COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis: www.mdpi.com/2036-7503/13/3/61.
Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34402228/
Myocarditis temporally associated with COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34133885/
Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: pubmed.ncbi.nlm.nih.gov/34219532/
Acute myocarditis associated with COVID-19 vaccination: report of a case: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/
Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: pubmed.ncbi.nlm.nih.gov/34840235/.
Myocarditis in the setting of a recent COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34712497/.
Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext.
Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/
Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408.
Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: www.mdpi.com/2075-4426/11/11/1106
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/
Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/
Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34615534/
Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: pubmed.ncbi.nlm.nih.gov/34352418/
Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.
CAd26.COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: pubmed.ncbi.nlm.nih.gov/34632750/
Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: haematologica.org/article/view/haematol.2021.279075
COVID-19 vaccine-induced thrombosis: pubmed.ncbi.nlm.nih.gov/34802488/.
Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: pubmed.ncbi.nlm.nih.gov/34887867/.
Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34863404/.
Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience: www.sciencedirect.com/science/article/pii/S235255682100093X
Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34876440/
Deep venous thrombosis more than two weeks after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33928773/
Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34880826/
Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34587242/
Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: pubmed.ncbi.nlm.nih.gov/34868465/
Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34097311/
Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: pubmed.ncbi.nlm.nih.gov/34820232/.
Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: onlinelibrary.wiley.com/doi/10.1002/ajh.26258
Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: pubmed.ncbi.nlm.nih.gov/34579636/
Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: pubmed.ncbi.nlm.nih.gov/34614491/
Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: pubmed.ncbi.nlm.nih.gov/34790684/
Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): pubmed.ncbi.nlm.nih.gov/33624509/.
Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): pubmed.ncbi.nlm.nih.gov/34612003/
Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: pubmed.ncbi.nlm.nih.gov/34096082/
Myocarditis associated with COVID-19 vaccination in three adolescent boys: pubmed.ncbi.nlm.nih.gov/34851078/.
Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34496880/
Perimyocarditis...
*
Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: pubmed.ncbi.nlm.nih.gov/34849657/.
Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: pubmed.ncbi.nlm.nih.gov/34664804/
Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: pubmed.ncbi.nlm.nih.gov/34605853/
Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: pubmed.ncbi.nlm.nih.gov/34166671/
Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34744118/
Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: pubmed.ncbi.nlm.nih.gov/34334935/.
Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34746968/
Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: pubmed.ncbi.nlm.nih.gov/34333695/.
Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34180390/
Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: pubmed.ncbi.nlm.nih.gov/34185045/
Myocarditis after BNT162b2 vaccination in a healthy male: pubmed.ncbi.nlm.nih.gov/34229940/
Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: pubmed.ncbi.nlm.nih.gov/34133825/
Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34308326/.
Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: pubmed.ncbi.nlm.nih.gov/34866106/
Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: pubmed.ncbi.nlm.nih.gov/34487236/
Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: pubmed.ncbi.nlm.nih.gov/34848416/
Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: pubmed.ncbi.nlm.nih.gov/34636504/
Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34367386/
Acute myocarditis in a young adult two days after vaccination with Pfizer: pubmed.ncbi.nlm.nih.gov/34709227/
Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: pubmed.ncbi.nlm.nih.gov/34778411/
Acute myocarditis after 2019 coronavirus disease vaccination: pubmed.ncbi.nlm.nih.gov/34734821/
A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: pubmed.ncbi.nlm.nih.gov/34246585/
Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: pubmed.ncbi.nlm.nih.gov/34228985/
Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34852213/
Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: pubmed.ncbi.nlm.nih.gov/34866122/
Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: pubmed.ncbi.nlm.nih.gov/34601566/
Myocarditis following COVID-19 vaccination: MRI study: pubmed.ncbi.nlm.nih.gov/34739045/.
Acute myocarditis after COVID-19 vaccination: case report: docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e
Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: pubmed.ncbi.nlm.nih.gov/34374740/
Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: pubmed.ncbi.nlm.nih.gov/34865500/
Myocarditis following vaccination with Covid-19 in a large healthcare organization: pubmed.ncbi.nlm.nih.gov/34614329/
AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: pubmed.ncbi.nlm.nih.gov/34560365/
COVID-19, Guillain-Barré and vaccineA dangerous mix: pubmed.ncbi.nlm.nih.gov/34108736/.
Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: pubmed.ncbi.nlm.nih.gov/34796417/.
Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: link.springer.com/article/10.1007/s10072-021-05523-5.
COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy: onlinelibrary.wiley.com/doi/10.1002/ana.26258.
Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: jamanetwork.com/journals/jama/fullarticle/2785009
A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34567447/
Guillain-Barré syndrome associated with COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34648420/.
Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: jamanetwork.com/journals/jamaneurology/fullarticle/2783708
Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: www.pedneur.com/article/S0887-8994(21)00221-6/fulltext.
Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34114256/.
Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34767184/.
Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: pubmed.ncbi.nlm.nih.gov/34644738/.
Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: pubmed.ncbi.nlm.nih.gov/34649856/
A rare case of Guillain-Barré syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34671572/
Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33758714/
COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: pubmed.ncbi.nlm.nih.gov/34484780/
Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; pubmed.ncbi.nlm.nih.gov/34779385/.
Miller Fisher syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34817727/.
Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: pubmed.ncbi.nlm.nih.gov/34789193/.
Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261746/
Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: pubmed.ncbi.nlm.nih.gov/34217513/.
*
Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: pubmed.ncbi.nlm.nih.gov/34579259/
A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: pubmed.ncbi.nlm.nih.gov/34370408/.
A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34703690/.
Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: pubmed.ncbi.nlm.nih.gov/34810163/
Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: onlinelibrary.wiley.com/doi/10.1002/ana.26218.
Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34482455/.
Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34114269/.
Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: pubmed.ncbi.nlm.nih.gov/34722067/
Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: pubmed.ncbi.nlm.nih.gov/33968610/
SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: pubmed.ncbi.nlm.nih.gov/34525410/
Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: pubmed.ncbi.nlm.nih.gov/34808658/
Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/ful.
Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: pubmed.ncbi.nlm.nih.gov/34522557/
Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34763263/.
Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: pubmed.ncbi.nlm.nih.gov/34621891/
Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34697502/
Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: pubmed.ncbi.nlm.nih.gov/33858693/
Acute transverse myelitis following inactivated COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34370410/
Acute transverse myelitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34579245/.
A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: pubmed.ncbi.nlm.nih.gov/34182207/
Post COVID-19 transverse myelitis; a case report with review of the literature: pubmed.ncbi.nlm.nih.gov/34457267/.
Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: pubmed.ncbi.nlm.nih.gov/34189662/
Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: pubmed.ncbi.nlm.nih.gov/34660149/
Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34131771/
A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: pubmed.ncbi.nlm.nih.gov/34635376/
Acute pericarditis and cardiac tamponade after vaccination with Covid-19: pubmed.ncbi.nlm.nih.gov/34749492/
Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34849667/
Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34319393/
Acute myopericarditis after COVID-19 vaccine in adolescents: pubmed.ncbi.nlm.nih.gov/34589238/
Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34149145/
Case report: symptomatic pericarditis post COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34693198/.
An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient: pubmed.ncbi.nlm.nih.gov/34797392/
Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): pubmed.ncbi.nlm.nih.gov/34862234/
Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: pubmed.ncbi.nlm.nih.gov/34396358/.
Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34848426/.
Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/33946748/
Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34591186/
Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34352309/
Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: pubmed.ncbi.nlm.nih.gov/34804803/.
Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: pubmed.ncbi.nlm.nih.gov/34077572/
Retinal hemorrhage after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34884407/.
Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34859017/
Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: pubmed.ncbi.nlm.nih.gov/34783899/
Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34549178/.
Brain death in a vaccinated patient with COVID-19 infection: pubmed.ncbi.nlm.nih.gov/34656887/
Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34236717/.
Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34729467/.
A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/33932458/
Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: pubmed.ncbi.nlm.nih.gov/34092400/742.
Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34754937/
Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: pubmed.ncbi.nlm.nih.gov/33771584/
Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34846583/
COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: pubmed.ncbi.nlm.nih.gov/34073536/
Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: pubmed.ncbi.nlm.nih.gov/34411532/
Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval: www.medrxiv.org/content/10.1101/2021.12.02.21267156v1
Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: pubmed.ncbi.nlm.nih.gov/33851711/
Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: pubmed.ncbi.nlm.nih.gov/34675550/.
Anaphylaxis after Modern COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34734159/.
Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34698847/
Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: pubmed.ncbi.nlm.nih.gov/34020815/
Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: pubmed.ncbi.nlm.nih.gov/33641264/
Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: pubmed.ncbi.nlm.nih.gov/33641268/
Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: pubmed.ncbi.nlm.nih.gov/33834172/
Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: pubmed.ncbi.nlm.nih.gov/34579211/
Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: pubmed.ncbi.nlm.nih.gov/34343674/
Acute myocardial infarction and myocarditis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34586408/
Takotsubo syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34539938/.
Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: pubmed.ncbi.nlm.nih.gov/34731486/.
Premature myocardial infarction or side effect of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33824804/
Myocardial infarction, stroke, and pulmonary embolism...